What is. PrenatalSAFE Karyo test is the most technologically advanced genome-wide NIPT
|
|
|
- Theresa McBride
- 7 years ago
- Views:
Transcription
1
2 What is PrenatalSAFE Karyo test is the most technologically advanced genome-wide NIPT Through cfdna analysis from maternal plasma, PrenatalSAFE Karyo detects: Aneuploidies structural chromosomal aberrations (deletions or duplications) across the fetal genome providing karyotype-level insight.
3 the next level in noninvasive prenatal testing PrenatalSafe Karyo analyzes every chromosome in the genome. Unlike any other noninvasive prenatal test available to date, it offers a level of information previously only available from a fetal karyotype analysis, performed with invasive prenatal diagnosis procedures (amniocentesis and CVS)
4 NIPT uses cell-free DNA (cfdna) Maternal blood sample Maternal cfdna Fetal cfdna
5 Whole-genome sequencing technology cfdna extraction Fetal Fraction determination DNA Sequences counting
6 2 levels of genome-wide screening It can also test for 9 common microdeletion syndromes Microdeletion Syndrome Prevalence DiGeorge syndrome (22q11.2) 1 in 4,000 1p36 deletion syndrome 1 in 4,000 to 1 in 10,000 Angelman syndrome (15q11.2) 1 in 12,000 Prader-Willi syndrome (15q11.2) 1 in 10,000 to 1 in 25,000 Cri du Chat syndrome (5p15.3) 1 in 20,000 to 1 in 50,000 Wolf-Hirschhorn syndrome (4p16.3) 1 in 50,000 Langer-Giedion syndrome (8q24) 1/ Jacobsen syndrome (11q23) 1/ Smith-Magenis syndrome (17p11.2) 1/ /25.000
7 Detection rate
8 Detection rate PrenatalSAFE Karyo Plus test identifies 95.5% of chromosomal anomalies prenatally detected and 99.1% of those anomalies observed at birth, achieving a level of detection rate very closed to the traditional fetal karyotyping (96.9%), obtained with invasive, prenatal diagnostic techniques.
9 Conventional Prenatal Screening vs Detection Rates for Trisomy 21 Quadruple Screen 1st Trimester Blood Screen + NT Serum Integrated False Positive Rate (FPR): 5% Integrated Screen ACOG Practice Bulletin No. 77, January 2007
10 Fetal Karyotyping vs Analyzes every chromosome Traditional Karyotyping Detects chromosomal gains or losses >7 Mb Detects chromosome gains or losses >10 Mb Requires an invasive procedure Detects unbalanced translocations Detects segmental deletions/duplications Detects mosaic trisomies Detects marker chromosomes Detects microdeletion syndromes Detects triploidy Considered diagnostic
11 Pre-clinical Validation performance Trisomy 21 (n=1419) Trisomy 18 (n=1419) Trisomy 13 (n=1419) SCA (n=1419) CNV (n=1419) True Positive False Positive True Negative False Negative Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) (96.38% %) (99.72% %) (96.38% %) (99.72% %) (88.78% %) (99.73% %) (88.78% %) (99.73% %) (76.84% %) (99.74% %) (76.84% %) (99.74% %) (90.26% to %) (99.73% to %) (90.26% to %) (99.73% to %) (90.51% to %) (99.73% to %) (90.51% to %) (99.73% to %) PPV: Positive Predictive Value; NPV: Negative Predictive Value; SCA: Sex Chromosomes Aneuploidy. CNV: Copy Number Variation Fiorentino et al., EJHG conference 2016; ISPD conference 2016
12 Performance Standard protocol Follow-up March 2016 PPV: Positive Predictive Value; NPV: Negative Predictive Value; SCA: Sex Chromosomes Aneuploidy
13 Performance FAST protocol Follow-up March 2016 PPV: Positive Predictive Value; NPV: Negative Predictive Value; SCA: Sex Chromosomes Aneuploidy
14 Published validation studies
15 This test is intended for patients at 10 weeks or greater gestation who meet any of the following criteria: Maternal age-related risks (e35 years) Positive results on maternal serum screening Abnormal ultrasound finding(s) Prior pregnancy with aneuploidy Parental translocation Low risk pregnancies Patients wanting early, accurate testing and are at average risk of aneuploidy Which Patients Should Be Offered?
16 pregnancy characteristics The test is suitable for both single and twin pregnancies. It can be performed in patients whose pregnancies have been achieved by IVF techniques, including pregnancies with egg donation.
17 Free services supplied
18 Case study
19 Case Study 1 31 y.o. patient 12^ weeks gestation 5 Negative Result 20^ week gestation Fetal abnormal ultrasound findings (cerebellar ipoplasia; Ventriculomegaly ) Amniocentesis Reassessment of the NIPT data with
20 Chr. 5 Detection of a deletion 5p confirmed by array-cgh Chr. 5 del5p15.33p Mb Amniotic Fluid cfdna Array-CGH PrenatalSafe Karyo
21 Case Study 2 32 y.o. patient 13^ weeks gestation 5 Negative Result 21^ weeks gestation Multiple fetal abnormal ultrasound findings Reassessment of the NIPT data with Amniocentesis
22 Chr. 18 Identification of 2 deletions (18p / 18q) confirmed by array-cgh Chr. 18 Del18p11.32-p Mb Amniotic Fluid cfdna Del18q21.32-q Mb Array-CGH PrenatalSafe Karyo
23 Case Study 3 32 y.o patient Carrier of a reciprocal translocation 46,XX,t(7;9)(p15;q22) 11^ weeks gestation Chr. 7 Chr. 9 Abnormal Result detected fetal karyotype with an unbalanced translocation Villocentesis Results confirmed
24 Detected a fetal karyotype with an unbalanced translocation confirmed by array-cgh Dup7p22.3p Mb Dup9p24.3-q Mb Array-CGH PrenatalSafe Karyo Array-CGH PrenatalSafe Karyo CVS cfdna CVS cfdna
25 Case Study 4 35 y.o patient 13^ weeks gestation Amniocentesis (traditional karyotyping) Negative Result (Fetale karyotype 46, XY) (Suspected DiGeorge syndrome) 20^ weeks gestation Fetal abnormal ultrasound findings Identified deletion 22q11.2 (compatible with DiGeorge syndrome) Amniocentesis
26 Plus Identification of 22q11.2 deletion confirmed by Array-CGH Chr.22 del22q11.21 DiGeorge Syndrome 4 Mb Amniotic Fluid cfdna Array-CGH PrenatalSafe Karyo
27 Case Study 5 Chr. 13 Chr y.o. patient (She was not aware to be carrier of a chromosomal translocation) 12^ weeks gestation Abnormal Result detected fetal karyotype with an unbalanced translocation Villocentesis Paziente portatrice di traslocazione reciproca 46,XX,t(13;20)(q33;q13.3) Results confirmed
28 Detected a fetal karyotype with an unbalanced translocation confirmed by array-cgh Del13q33.1q Mb Dup20q Mb Chr. 13 Chr. 20 PrenatalSafe Karyo (cfdna) Array-CGH (CVS) PrenatalSafe Karyo (cfdna) Array-CGH (CVS)
29 Case Study 6 40 y.o. patient 13^ weeks gestation NIPT (5 chromosomes screening) Positive Result High risk for Trisomy 21 Test performed by a different lab Trisomy 21 not detected Maternal CNV detected causing the false positive result
30 Lower the risk of false positive results determined by maternal CNVs Array-CGH Maternal blood PrenatalSafe Karyo cfdna
Non-Invasive Prenatal Testing (NIPT) Factsheet
Introduction NIPT, which analyzes cell-free fetal DNA circulating in maternal blood, is a new option in the prenatal screening and testing paradigm for trisomy 21 and a few other fetal chromosomal aneuploidies.
your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing.
your questions answered the reassurance of knowing A guide for parents-to-be on noninvasive prenatal testing. Accurate answers about your baby s health simply, safely, sooner. What is the verifi Prenatal
Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions Using Cell-Free Fetal DNA
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Noninvasive Prenatal Screening for Fetal Aneuploidies and Microdeletions
A test your patients can trust. A company you know and trust.
A test your patients can trust. A company you know and trust. informaseq Prenatal Test an advanced, non-invasive, prenatal screening for T21, T18, and T13 chromosomal aneuploidies using next generation
LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES. Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD
LEUKODYSTROPHY GENETICS AND REPRODUCTIVE OPTIONS FOR AFFECTED FAMILIES Leila Jamal, ScM Kennedy Krieger Institute, Baltimore MD 2 Outline Genetics 101: Basic Concepts and Myth Busting Inheritance Patterns
A test your patients can trust.
A test your patients can trust. A simple, safe, and accurate non-invasive prenatal test for early risk assessment of Down syndrome and other conditions. informaseq Prenatal Test Simple, safe, and accurate
RECURRENT PREGNANCY LOSS DR.RAJALAKSHMI SRINIVASAN SPECIALIST GYNECOLOGIST ZULEKHA HOSPITAL DUBAI
RECURRENT PREGNANCY LOSS DR.RAJALAKSHMI SRINIVASAN SPECIALIST GYNECOLOGIST ZULEKHA HOSPITAL DUBAI RECURRENT PREGNANCY LOSS -RM Clinically recognized consecutive or non consecutive pregnancy losses before
Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA
Noninvasive Prenatal Testing for Fetal Aneuploidies Using Cell- Free Fetal DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST
Executive summary. Current prenatal screening
Executive summary Health Council of the Netherlands. NIPT: dynamics and ethics of prenatal screening. The Hague: Health Council of the Netherlands, 2013; publication no. 2013/34. In recent years, new tests
Clinical Studies Abstract Booklet
Clinical Studies Abstract Booklet The Harmony Prenatal Test is a non-invasive prenatal test (NIPT) that assesses the risk of trisomies by analyzing cell-free DNA (cfdna) in maternal blood. Since January
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA
CHROMOSOMES Dr. Fern Tsien, Dept. of Genetics, LSUHSC, NO, LA Cytogenetics is the study of chromosomes and their structure, inheritance, and abnormalities. Chromosome abnormalities occur in approximately:
Chromosomes, Karyotyping, and Abnormalities (Learning Objectives) Learn the components and parts of a metaphase chromosome.
Chromosomes, Karyotyping, and Abnormalities (Learning Objectives) Learn the components and parts of a metaphase chromosome. Define the terms karyotype, autosomal and sex chromosomes. Explain how many of
Invasive Prenatal (Fetal) Diagnostic Testing
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Invasive Prenatal (Fetal) Diagnostic Testing Number 12.04.116
The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands
FVV in ObGyn, 2014, 6 (1): 7-12 Preliminary report The first 3,000 Non-Invasive Prenatal Tests (NIPT) with the Harmony test in Belgium and the Netherlands P.J. Willems 1, H. Dierickx 1, ES. Vandenakker
Basic Human Genetics: Reproductive Health and Chromosome Abnormalities
Basic Human Genetics: Reproductive Health and Chromosome Abnormalities Professor Hanan Hamamy Department of Genetic Medicine and Development Geneva University Switzerland Training Course in Sexual and
Cytogenetic and Molecular Diagnosis in Gestational Disorders
Cytogenetic and Molecular Diagnosis in Gestational Disorders Katherine Geiersbach, M.D. Assistant Professor, Department of Pathology University of Utah School of Medicine Medical Director, Cytogenetics
Gutenberg Center in MALAGA
Introduction Gutenberg Center in MALAGA Gutenberg Center in Málaga opened in 1987 as a clinic to provide integral assisstance for women, divided into 6 Units, specialized in the different aspects of Obs
Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA
Sequencing-based Tests to Determine Trisomy 21 from Maternal Plasma DNA Policy Number: Original Effective Date: MM.03.006 09/01/2013 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST 09/01/2013
MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA
Scuola di specializzazione in Genetica Medica Journal Club 14 gennaio 2014 MASSIVELY PARALLEL SEQUENCING OF MATE RNAL PLASMA DNA IN 113 CASES OF FETAL NUCHAL CYSTIC HYGROMA Bianchi, Diana W. MD; Prosen,
Each person normally has 23 pairs of chromosomes, or 46 in all. We inherit one chromosome per pair from our mother and one from our father.
AP Psychology 2.2 Behavioral Genetics Article Chromosomal Abnormalities About 1 in 150 babies is born with a chromosomal abnormality (1, 2). These are caused by errors in the number or structure of chromosomes.
Non-invasive prenatal detection of chromosome aneuploidies using next generation sequencing: First steps towards clinical application
Non-invasive prenatal detection of chromosome aneuploidies using next generation sequencing: First steps towards clinical application PD Dr. rer. nat. Markus Stumm Zentrum für Pränataldiagnostik Kudamm-199
Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists Prenatal screening and diagnosis of chromosomal and genetic abnormalities in the fetus in pregnancy This statement has been
Supporting Information
Supporting Information Yin et al. 10.1073/pnas.1518151112 Fig. S1. Characteristic Z scores of a section of DNA encompassing a deletion in sample 14,945 at (A) varying concentrations of abnormal DNA at
First Trimester Screening for Down Syndrome
First Trimester Screening for Down Syndrome What is first trimester risk assessment for Down syndrome? First trimester screening for Down syndrome, also known as nuchal translucency screening, is a test
Prenatal Testing Special tests for your baby during pregnancy
English April 2006 [OTH-7750] There are a number of different prenatal (before birth) tests to check the development of your baby. Each test has advantages and disadvantages. This information is for people
Genetic Counseling: A Profession in the Making. Jessica Hooks, MS Genetic Counselor University of South Carolina
Genetic Counseling: A Profession in the Making Jessica Hooks, MS Genetic Counselor University of South Carolina Definition the process of helping people understand and adapt to the medical, psychological
COMMITTEE OPINION. Cell-free DNA Screening for Fetal Aneuploidy
The American College of Obstetricians and Gynecologists WOMEN S HEALTH CARE PHYSICIANS (Published Electronically Ahead of Print on June 26, 2015) COMMITTEE OPINION Number 640 September 2015 (This Committee
cfdna in maternal plasma obtained from a population undergoing routine screening at 11-13 weeks gestation.
Reports of Major Impact www.ajog.org Noninvasive prenatal testing for fetal trisomies in a routinely screened first-trimester population Kypros H. Nicolaides, MD; Argyro Syngelaki, RM; Ghalia Ashoor, MD;
REI Pearls: Pitfalls of Genetic Testing in Miscarriage
The Skinny: Genetic testing of miscarriage tissue is controversial and some people question if testing is helpful or not. This summary will: 1) outline the arguments for and against genetic testing; 2)
Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy
Genetics in Family Medicine: The Australian Handbook for General Practitioners Testing and pregnancy Testing and pregnancy GP s role 3 Counselling before and during pregnancy 3 Collecting the family history
National Down Syndrome Society
National Down Syndrome Society The national advocate for the value, acceptance and inclusion of people with Down syndrome What is Down Syndrome? Down syndrome is the most commonly occurring chromosomal
The following chapter is called "Preimplantation Genetic Diagnosis (PGD)".
Slide 1 Welcome to chapter 9. The following chapter is called "Preimplantation Genetic Diagnosis (PGD)". The author is Dr. Maria Lalioti. Slide 2 The learning objectives of this chapter are: To learn the
Fluorescence in situ hybridisation (FISH)
Fluorescence in situ hybridisation (FISH) rarechromo.org Fluorescence in situ hybridization (FISH) Chromosomes Chromosomes are structures that contain the genetic information (DNA) that tells the body
Overview of Genetic Testing and Screening
Integrating Genetics into Your Practice Webinar Series Overview of Genetic Testing and Screening Genetic testing is an important tool in the screening and diagnosis of many conditions. New technology is
Chromosomes, Mapping, and the Meiosis Inheritance Connection
Chromosomes, Mapping, and the Meiosis Inheritance Connection Carl Correns 1900 Chapter 13 First suggests central role for chromosomes Rediscovery of Mendel s work Walter Sutton 1902 Chromosomal theory
In most developed countries, prenatal screening
Genome-Wide Fetal Aneuploidy Detection by Maternal Plasma DNA Sequencing Diana W. Bianchi, MD, Lawrence D. Platt, MD, James D. Goldberg, MD, Alfred Z. Abuhamad, MD, Amy J. Sehnert, MD, and Richard P. Rava,
Prenatal screening and diagnostic tests
Prenatal screening and diagnostic tests Contents Introduction 3 First trimester routine tests in the mother 3 Testing for health conditions in the baby 4 Why would you have a prenatal test? 6 What are
New Prenatal Tests for Down Syndrome: Brian G. Skotko, MD, MPP Co-Director, Down Syndrome Program Massachusetts General Hospital
New Prenatal Tests for Down Syndrome: International Updates and What This All Means for Your Family Brian G. Skotko, MD, MPP Co-Director, Down Syndrome Program Massachusetts General Hospital Band of Angels
Trisomy 13 (also called Patau s syndrome or T13)
Screening Programmes Fetal Anomaly Trisomy 13 (also called Patau s syndrome or T13) Information for parents Publication date: April 2012 Review date: April 2013 Version 2 117 Information sheet to help
The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report
0 The National Down Syndrome Cytogenetic Register for England and Wales: 2008/9 Annual Report Joan K Morris, Elizabeth De Souza December 2009 National Down Syndrome Cytogenetic Register Queen Mary University
Consent to Perform Preimplantation Genetic Screening (PGS) using. Comparative Genomic Hybridization (acgh) or Next Generation Sequencing (NGS)
Consent to Perform Preimplantation Genetic Screening (PGS) using Array Comparative Genomic Hybridization (acgh ) or Next Generation Sequencing (NGS) Purpose The purpose of Preimplantation Genetic Screening
VILLOCENTESI O AMNIOCENTESI? Vantaggi e svantaggi da una esperienza di 115 000 analisi cromosomiche prenatali
VILLOCENTESI O AMNIOCENTESI? Vantaggi e svantaggi da una esperienza di 115 000 analisi cromosomiche prenatali Prof. Giuseppe SIMONI TOMA, Advanced Biomedical Assays, S.p.A. Controversie e nuove tecnologie
Chromosomal Abnormalities
Chromosomal Abnormalities George E Tiller, MD, PhD Regional Chief, Dept. Genetics Southern California Permanente Medical Group Los Angeles, CA Objectives of Lecture list several indications for karyotyping
1. PRENATAL DIAGNOSIS OF CHROMOSOMAL DISORDERS - molecular aspects
1. PRENATAL DIAGNOSIS OF CHROMOSOMAL DISORDERS - molecular aspects Ana Stavljenić-Rukavina Zagreb University School of Medicine, Croatia The standard measures for population health outcomes is based on
The 11 13 +6 weeks scan
The 11 13 +6 weeks scan Kypros H. Nicolaides The 11 13 +6 weeks scan Fetal Medicine Foundation, London 2004 Dedication to Herodotos & Despina Contents Introduction 1. First trimester diagnosis of chromosomal
The genetic screening of preimplantation embryos by comparative genomic hybridisation
Vol. 11, Suppl. 3 51 The genetic screening of preimplantation embryos by comparative genomic hybridisation Maria V Traversa 1, James Marshall, Steven McArthur, Don Leigh Genea, Sydney, Australia Received:
Obstetrical Ultrasound and Prenatal Diagnostic Center
Obstetrical Ultrasound and Prenatal Diagnostic Center Prenatal Diagnosis: Options and Opportunities Learn about various screening options including Early Risk Assessment (ERA), now available to women of
The California Prenatal Screening Program
The California Prenatal Screening Program Provider ook netic Disease Screening Program Quad Marker Screening Serum Integrated Screening Full Integrated Screening TABLE OF CONTENTS WELCOME to the California
The California Prenatal Screening Program
The California Prenatal Screening Program Quad Marker Screening One blood specimen drawn at 15 weeks - 20 weeks of pregnancy (second trimester) Serum Integrated Screening Prenatal Patient Booklet - English
Position Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis, April 2013
Position Statement from the Aneuploidy Screening Committee on Behalf of the Board of the International Society for Prenatal Diagnosis, April 2013 Peter Benn (Chair), Antoni Borell, Rossa Chiu, Howard Cuckle,
Complimentary and personal copy for
Complimentary and personal copy for www.thieme.com Publishing House and Copyright: 2015 by Georg Thieme Verlag KG Rüdigerstraße 14 70469 Stuttgart ISSN Any further use only by permission of the Publishing
Optimal Detection of Fetal Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal Blood
Clinical Chemistry 57:7 1042 1049 (2011) Molecular Diagnostics and Genetics Optimal Detection of Fetal Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal
*Please consult the online schedule for this course for the definitive date and time for this lecture.
CHROMOSOMES AND DISEASE Date: September 29, 2005 * Time: 8:00 am- 8:50 am * Room: G-202 Biomolecular Building Lecturer: Jim Evans 4200A Biomolecular Building jpevans@med.unc.edu Office Hours: by appointment
Preimplantation Genetic Diagnosis (PGD) for Fanconi Anemia and HLA matching
Preimplantation Genetic Diagnosis (PGD) for Fanconi Anemia and HLA matching Andria G. Besser, BEd, MS, CGC Licensed Genetic Counselor Reproductive Genetics Institute Chicago, IL Outline PGD overview In
Chapter 9 Diagnostic testing for trisomy 18
Chapter 9 Diagnostic testing for trisomy 18 9.1 Diagnostic procedures: amniocentesis Introduction: An amniocentesis procedure involves the use of a small gauge needle inserted through the woman s abdomen
Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma
No. 287, February 2013 Current Status in Non-Invasive Prenatal Detection of Down Syndrome, Trisomy 18, and Trisomy 13 Using Cell-Free DNA in Maternal Plasma This committee opinion has been prepared by
Genetics and Pregnancy Loss
Genetics and Pregnancy Loss Dorothy Warburton Genetics and Development (in Pediatrics) Columbia University, New York Estimates of Pregnancy Loss from Conception 1000 fertilized eggs (27% are lost) 728
Wissenschaftliche Highlights der GSF 2007
H Forschungszentrum für Umwelt und Gesundheit GmbH in der Helmholtzgemeinschaft Wissenschaftlich-Technische Abteilung Wissenschaftliche Highlights der GSF 2007 Abfrage Oktober 2007 Institut / Selbst. Abteilung
Chromosomal Microarray Analysis (CMA)
Chromosomal Microarray Analysis (CMA) Medical Genetics Laboratories Department of Molecular and Human Genetics Baylor College of Medicine Table of Contents Overview of CMA Examples of Common Findings Examples
Human Chromosomes lab 5
Human Chromosomes lab 5 Objectives Upon completion of this activity, you should be able to: describe the structure of human chromosomes with reference to size, centromere position, and presence or absence
Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method
Trisomy 13 detection in the first trimester of pregnancy using a chromosome-selective cell-free DNA analysis method Ghalia ASHOOR 1, Argyro SYNGELAKI 1, Eric WANG 2, Craig STRUBLE 2, Arnold OLIPHANT 2,
Clinical Policy Title: Array comparative genomic hybridization testing
Clinical Policy Title: Array comparative genomic hybridization testing Clinical Policy Number: 02.01.03 Effective Date: Sept 1, 2015 Initial Review Date: May 13, 2013 Most Recent Review Date: August 19,
A Guide to Prenatal Genetic Testing
Patient Education Page 29 A Guide to Prenatal Genetic Testing This section describes prenatal tests that give information about your baby s health. It is your choice whether or not to have these tests
Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System
TERATOLOGY 64:S20 S25 (2001) Inclusion of Early Fetal Deaths in a Birth Defects Surveillance System MATHIAS B. FORRESTER AND RUTH D. MERZ* Hawaii Birth Defects Program, Honolulu, Hawaii 96817 ABSTRACT
National Medical Policy
National Medical Policy Subject: Policy Number: Single Nucleotide Polymorphism (SNP) Chromosomal Microarray Analysis for Prenatal Testing and Intellectual Disability, Developmental Delay, and Multiple
Choosing Wisely. Obstetrics / Maternal Fetal Medicine Things Providers and Patients Should Question
Choosing Wisely Obstetrics / Maternal Fetal Medicine Things Providers and Patients Should Question Michelle Owens, MD, FACOG David Rindfusz, MD, FACOG April Bleich, MD, FACOG Kathleen Crowley, MD 1 Discuss
User guide for referring samples to the IBGRL Molecular Diagnostics Laboratory
International Blood Group Reference Laboratory (IBGRL) IBGRL provides specialist diagnostic services to NHS Blood and Transplant. The Molecular Diagnostics department is a CPA accredited laboratory and
Balanced. translocations. rarechromo.org. Support and Information
Support and Information Rare Chromosome Disorder Support Group, G1, The Stables, Station Rd West, Oxted, Surrey. RH8 9EE Tel: +44(0)1883 723356 info@rarechromo.org I www.rarechromo.org Balanced Unique
Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester
PRENATAL DIAGNOSIS Prenat Diagn 2000; 20: 390±394. Maternal serum free b-hcg and PAPP-A in fetal sex chromosome defects in the rst trimester Kevin Spencer 1 *, Natasha Tul 2 and Kypros H. Nicolaides 2
Fact Sheet 14 EPIGENETICS
This fact sheet describes epigenetics which refers to factors that can influence the way our genes are expressed in the cells of our body. In summary Epigenetics is a phenomenon that affects the way cells
Information leaflet. Centrum voor Medische Genetica. Version 1/20150504 Design by Ben Caljon, UZ Brussel. Universitair Ziekenhuis Brussel
Information on genome-wide genetic testing Array Comparative Genomic Hybridization (array CGH) Single Nucleotide Polymorphism array (SNP array) Massive Parallel Sequencing (MPS) Version 120150504 Design
Risk Calculation Software Requirements for Down's Syndrome Screening
Screening Programmes Fetal Anomaly Risk Calculation Software Requirements for Down's Syndrome Screening Version 1 January 2013 Created by: Dave Wright, Barry Nix, Steve Turner, David Worthington and Andy
The ultrasound detection of chromosomal anomalies 1
The ultrasound detection of chromosomal anomalies 1 Werther Adrian Clavelli, MD 2, Silvia Susana Romaris de Clavelli, MD 2, Philippe Jeanty, MD, PhD 3 Adapted from The Ultrasound Detection of Chromosomal
Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies
Ultrasound Obstet Gynecol 2013; 42: 34 40 Published online 7 June 2013 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/uog.12504 Implementation of maternal blood cell-free DNA testing in
4.2 Meiosis. Meiosis is a reduction division. Assessment statements. The process of meiosis
4.2 Meiosis Assessment statements State that meiosis is a reduction division of a diploid nucleus to form haploid nuclei. Define homologous chromosomes. Outline the process of meiosis, including pairing
fi АУ : fi apple Ав Ав АУ . apple, АУ fiав Ав. АК applefi АУ, АУАв Ав fi АУ apple fi Ав. А applefi АУ АУ АУ АсА» Ас Ам, длappleapple Ас...
АВАВАКдлАмА дла длама АсАядлАмА АВА АсдлАя & MАядлдлАмАК TА. 4, T. 2, АВ. 113-118, 2005 fi АУ : Аяapplefi. fiapple АсА» Ас Ам, длappleapple Ас..., Ая: Аяapplefi. fiapple, АВАУ Ас, АсА» Ас Ам длappleapple
CAGC Certification Logbook of Clinical Experience INSTRUCTIONS
CAGC Certification Logbook of Clinical Experience INSTRUCTIONS The purpose of the logbook is to show that the applicant has been significantly involved in the evaluation and counselling of patients seeking
VALIDATED MOLECULAR SOLUTIONS FOR CYTOGENETICISTS. PRODUCTS AND METHODOLOGIES Not for distribution in the USA
PRODUCTS AND METHODOLOGIES Not for distribution in the USA VALIDATED SOLUTIONS FOR MOLECULAR CYTOGENETICISTS 2 A GLOBAL LEADER IN HUMAN AND ENVIRONMENTAL HEALTH PerkinElmer is a global scientific leader
Trisomies 13 and 18. -Maternal age. (Patau and Edward s syndrome)
Trisomies 13 and 18 (Patau and Edward s syndrome) Trisomy 21 (Down syndrome) is the commonest chromosomal disorder at birth, and has been considered in detail in previous annual reports 23. Other relatively
UNIT 13 (OPTION) Genetic Abnormalities
Unit 13 Genetic Abnormailities 1 UNIT 13 (OPTION) Genetic Abnormalities Originally developed by: Hildur Helgedottir RN, MN Revised (2000) by: Marlene Reimer RN, PhD, CCN (C) Associate Professor Faculty
Chapter 8: Variation in Chromosome Structure and Number
Chapter 8: Variation in Chromosome Structure and Number Student Learning Objectives Upon completion of this chapter you should be able to: 1. Know the principles and terminology associated with variations
Sequencing and microarrays for genome analysis: complementary rather than competing?
Sequencing and microarrays for genome analysis: complementary rather than competing? Simon Hughes, Richard Capper, Sandra Lam and Nicole Sparkes Introduction The human genome is comprised of more than
General Guidelines and Quality Assurance for Cytogenetics
General Guidelines and Quality Assurance for Cytogenetics A common European framework for quality assessment for constitutional, acquired and molecular cytogenetic investigations. E.C.A. Permanent Working
Patient information on soft markers
Patient information on soft markers Before you read this section remember the following important points. The vast majority of babies with soft markers are normal. Soft markers are frequently seen in healthy
Birth defects. Report by the Secretariat
EXECUTIVE BOARD EB126/10 126th Session 3 December 2009 Provisional agenda item 4.7 Birth defects Report by the Secretariat 1. In May 2009 the Executive Board at its 125th session considered an agenda item
Triploidy. rarechromo.org
Triploidy rarechromo.org Triploidy Triploidy is a disorder that arises at conception when a baby starts life in the womb with a complete extra set of chromosomes. Chromosomes are the microscopically small
Ultrasonographic Diagnosis of Trisomy 18: Is It Practical in the Early Second Trimester?
Ultrasonographic Diagnosis of Trisomy 18: Is It Practical in the Early Second Trimester? Laurence E. Shields, MD, Leslie A. Carpenter, MS, CGC, Karin M. Smith, RDMS, Hanh V. Nghiem, MD The objective of
Prenatal Care Screening and Testing Guideline
Prenatal Care Screening and Testing Guideline Major Changes as of October 2013 2 Visit Schedule 2 Initial Visit 3 Second Trimester Visits (14 28 Weeks) 11 Third Trimester Visits (28 41 Weeks) 12 Postpartum
Carrier detection tests and prenatal diagnosis
Carrier detection tests and prenatal diagnosis There are several types of muscular dystrophy and about 50 neuromuscular conditions, all of which fall under the umbrella of the Muscular Dystrophy Campaign.
Preimplantation Genetic Diagnosis (PGD) and Childhood Diagnostic Evaluation
IG O Preimplantation Genetic Diagnosis (PGD) and Childhood Diagnostic Evaluation KD Carsten Bergmann carsten.bergmann@bioscientia.de carsten.bergmann@uniklinik-freiburg.de Controversies Conference on ADPKD
AND GENETIC TESTING FOR ALL... THE COMING REVOLUTION IN NON-INVASIVE PRENATAL GENETIC TESTING
AND GENETIC TESTING FOR ALL... THE COMING REVOLUTION IN NON-INVASIVE PRENATAL GENETIC TESTING Jaime S. King* For thousands of years, expecting parents have daydreamed of being able to know about their
IBGRL, NHSBT, Bristol
IBGRL, NHSBT, Bristol Valuable to know D type of fetus Fetus D-positive: at risk pregnancy should be managed appropriately Fetus D-negative: not at risk no need for intervention RHD RHCE RHD* D 37 bp
Roberto Ciccone, Orsetta Zuffardi Università di Pavia
Roberto Ciccone, Orsetta Zuffardi Università di Pavia XIII Corso di Formazione Malformazioni Congenite dalla Diagnosi Prenatale alla Terapia Postnatale unipv.eu Carrara, 24 ottobre 2014 Legend:Bluebars
Optional Tests Offered Before and During Pregnancy
Plano Women s Healthcare Optional Tests Offered Before and During Pregnancy Alpha-Fetoprotein Test (AFP) and Quad Screen These are screening tests that can assess your baby s risk of having such birth
Universal Fetal Cardiac Ultrasound At the Heart of Newborn Well-being
Universal Fetal Cardiac Ultrasound At the Heart of Newborn Well-being Optimizes detection of congenital heart disease (chd) in the general low risk obstetrical population Daniel J. Cohen, M.D. danjcohen@optonline.net
Western Public Health Casebook 2015
Western Public Health Casebook 2015 Cases from the Schulich Interfaculty Program in Public Health Editors Mark Speechley, PhD Professor Department of Epidemiology & Biostatistics Schulich Interfaculty
CONGENITAL HEART DISEASE
CONGENITAL HEART DISEASE Introduction Congenital heart disease (CHD) is the most common congenital disorder in newborns [1]. Due to definitional issues, there are large variations in prevalence estimates.
CONFIDENT CODING FOR OB/GYN CONFIDENT CODING FOR OB/GYN
Arlene J. Smith, CPC AAPC National Advisory Board 2007-2009 1 So when exactly does the global period start? Unraveling the confusion in antepartum care coding Correct coding for multiple gestations! Vaginal
Research. Currently, the most effective and
Research GENETICS Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18 Mary E. Norton, MD; Herb Brar, MD;
Preimplantation genetic diagnosis new method of screening of 24 chromosomes with the Array CGH method...2
August 2012 content 8 Preimplantation genetic diagnosis new method of screening of 24 chromosomes with the Array CGH method...2 Maintaining fertility new opportunities in GENNET...3 Hysteroscopy without